

VALUE FOCUS

Medtech & Device Industry

Fourth Quarter 2022

This quarterly update includes a broad outlook that divides the healthcare industry into four sectors: Biotechnology & Life Sciences, Medical Devices, Healthcare Technology, and Large, Diversified Healthcare Companies.

We include a review of market performance, valuation multiple trends, operating metrics, and other market data. This issue also includes a review of M&A and IPO activity during the third quarter of 2022.



Medtech & Device Industry Services

Mercer Capital provides valuation services to start ups, larger public and private companies, and private equity and venture capital funds.

Mercer Capital's expertise in the medtech and device industry spans the following segments:

- Biotechnology and life sciences
- Medical devices
- Healthcare technology
- Large, diversified

Our services include:

- Purchase price allocations
- Impairment testing
- Portfolio valuation for LP reporting
- Transaction and valuation advisory
- Equity compensation valuation for tax compliance

Contact a Mercer Capital professional to discuss your needs in confidence.

Contact Us



Sujan Rajbhandary, CFA
901.322.9749
sujanr@mercercapital.com



J. David Smith, ASA, CFA
713.239.1005
smithd@mercercapital.com



Travis W. Harms, CFA, CPA/ABV
901.322.9760
harmst@mercercapital.com



Daniel P. McLeod, CFA
901.322.9716
mcleodd@mercercapital.com



J. Davis Rolfe, Jr., CPA
901.322.9712
rolfed@mercercapital.com

Follow Mercer Capital



Mercer Capital



@MercerCapital

Copyright © 2022 Mercer Capital Management, Inc. All rights reserved. It is illegal under Federal law to reproduce this publication or any portion of its contents without the publisher's permission. Media quotations with source attribution are encouraged. Reporters requesting additional information or editorial comment should contact Barbara Walters Price at 901.685.2120. Mercer Capital's Industry Focus is published quarterly and does not constitute legal or financial consulting advice. It is offered as an information service to our clients and friends. Those interested in specific guidance for legal or accounting matters should seek competent professional advice. Inquiries to discuss specific valuation matters are welcomed. To add your name to our mailing list to receive this complimentary publication, visit our web site at www.mercercapital.com.

In This Issue

Industry Scan	1
Stock Market Performance	4
Revenue Multiples	7
EBITDA Multiples	8
Select Operating Metrics	9
Public Medical Device Companies	10
Mergers & Acquisitions	14
Initial Public Offerings	16

Learn More about Mercer Capital &
our Medtech & Device Services at
www.mercercapital.com

Industry Scan

By: Sujan Rajbhandary, CFA, ABV

For this quarterly update, we bring together a couple of strands of our medtech and device industry practice. First, as long-term observers, public market developments in 2022 were interesting and perhaps marked an inflection point for the short to medium term. Second, in October, we attended a medtech industry conference, where we were able to gather a rich set of perspectives. The implications for some of the larger companies in the space are probably clear-cut. The downstream reverberations to private, development stage companies may be less straightforward. Nevertheless, since development stage companies are typically constrained by currently available funds and continually contemplating the next funding round, these developments are of critical importance.

2022: A Brief Review

A tumultuous year in the public markets is coming to a close. By the end of the third quarter 2022, the S&P 500 was down nearly 25%, marking a near-bottom for the year. The broader medtech and devices industry largely followed suit. On the brighter side, established large, diversified companies, while lagging their own previous benchmarks, outperformed the broader market. As a group, some biotech and life sciences companies (see next section) also seemed to fare relatively well. A closer look reveals that within the group some of the larger companies with more diversified revenue bases and, perhaps more importantly, profitable operations performed much better than smaller companies promising higher growth but deferred profits.

Current profitability also appeared to differentiate better stock price performers among the medical device and healthcare technology companies. At the same time, negative sentiment was more apparent for wide swathes of these two groups compared to the broader industry. It is obvious in hindsight but over the course of 2022, as interest rates rose and remained high, markets seemed to prefer existing earnings and nearer-term cash flows over future (rosier) prospects.

The shift towards more caution also manifested in other measures of market sentiment and activity. Wholesale downward revisions of earnings (growth) estimates have not occurred so far (this may yet come to pass), so much of the price decline reflects compressing valuation multiples. The pace of M&A transactions, which had gone from strength to strength during 2020 and 2021 despite myriad disruptions and distractions, decelerated significantly in 2022. By our measure, total transactions volume in the industry through the first three quarters of 2022 was roughly equal to that of just the fourth quarter of 2021. The number of IPOs also slowed to a trickle.

Industry Scan

(cont.)

Looking Ahead to 2023 and Beyond: A Few Notes for Development Stage Companies

No industry is an island but as we and others have pointed out, **several long-term trends**, demographic and otherwise, suggest a favorable overall outlook for the medtech and device space. Even against the seemingly dour recent market backdrop, a multitude of attendees at the medtech conference agreed on the relative merits of the industry compared to the broader economy and market. We work with a number of development stage medtech and device companies over the course of a typical year. From that perspective, we find the long-term trends interesting because of the structural emphasis on continual innovation that improve outcomes for patients and clinicians.

A defining feature of medtech innovation funding is that it occurs over multiple tranches as the technologies and companies achieve various developmental milestones. In this context, some observations for development stage companies:

- » An obvious first order effect of the recent public market developments over the past year is that development stage companies should expect generally lower valuations for funding rounds (at least) over the next couple of years.
- » Lackluster exit activity, via either M&A or IPO, delays and/or reduces deployable capital for venture capital funds, which will make them more cautious in considering investment decisions.
- » The sentiment shift towards more caution is shared by all investors, although the degrees will differ. Accordingly, in addition to valuation compression, some types of companies (for example, those at the pre-clinical stage) will find fundraising to be extremely difficult.
- » As a corollary, investors are likely to prize clean clinical data. Companies focused on demonstrating good clinical outcomes will be better prepared for future funding rounds.

Industry Scan

(cont.)

- » Similarly, companies that can stretch their existing funds until they can achieve a good (clinical) milestone will be better rewarded in the next funding round.
- » Commercial traction after hurdling regulatory approval remains an important structural consideration, especially for the non-corporate investors.

Wrap-up

Beyond the near-term market dynamics, a key conference takeaway for us was that the medtech funding eco-system is deep and diverse. We met and heard from traditional venture capital investors, corporate investors, and folks who operate in the continuum between them. The goals for the various investors differ to some degree, with some focused on financial attributes while others (like corporate VCs) include strategic considerations in the mix. Investors with broader goals and considerations are, to an extent, less sensitive to the prevailing market conditions and can afford to take a longer-term view. Even among these investors, financial terms and preferred deal structures vary considerably.

For development stage companies contemplating fundraising efforts, a deep and diverse investor eco-system can provide plenty of optionality. In keeping with a recurring theme of this update, a note of caution – evaluating a potential funding round requires both an examination of the financial terms and an understanding of the structural features and their longer-term implications.

Mercer Capital has broad experience in providing valuation services to medtech and device start-ups, larger public and private companies, and private equity and venture capital funds involved in the sector. Please contact us to discuss how we may be of help.



Sujan Rajbhandary, CFA, ABV

(901) 322-9749 | sujanr@mercercapital.com

Stock Market Performance


The S&P 500 declined 5.3% during the third quarter of 2022 as the market downturn that began earlier in the year gathered pace. Two of four medtech industry sub-sectors tracked by Mercer Capital performed roughly in line with the broader index over 3Q22. The healthcare technology group was a notable straggler. The biotechnology and life sciences group outperformed all other groups as well as the S&P 500. Similar trends were observed for the various sub-sectors since the beginning of the year. The large diversified, and biotechnology and life sciences groups, while down on an absolute basis, outperformed the broader market over the prior nine months. Medical device and healthcare technology companies were among the most battered in the wider medtech space.

- A market-capitalization weighted index of companies included in our biotechnology and life sciences sub-sector gained 2.5% over the quarter ended September 2022. The top performer of the group was Biogen, Inc., which posted a 30.9% return. BIIB is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
- The medical device index declined 4.5% in 3Q22. The group's best performer was Resmed, Inc., which returned 4.3%. RMD is a San Diego, California-based medical equipment company which primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease, and other respiratory conditions.
- The healthcare technology index decreased 14.2% over the period. Tabula Rasa Healthcare, up 86.8%, outperformed all other constituents of the group. TRHC is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
- The group of large, diversified companies decreased 5.6% over the quarter. The top performer within the group was Agilent Technologies, which increased 2.5% during the period. Agilent is an American life sciences company that provides instruments, software, services, and consumables for the entire laboratory workflow.

Stock Market Performance

(cont.)

3Q 2022 Stock Price Performance




Individual sub-sector performance represented by market capitalization weighted indices for each group.

Data Source: Bloomberg LP; Mercer Capital Analysis


Stock Market Performance

(cont.)

YTD Stock Price Performance



LTM Stock Price Performance



Individual sub-sector performance represented by market capitalization weighted indices for each group.
Source: Bloomberg LP; Mercer Capital Analysis


Revenue Multiples

■ 75% Quartile ■ Median ■ 25% Quartile

Median Revenue multiples from each MCM group. Data source: Bloomberg


Biotechnology & Life Sciences

EV / Trailing LTM Revenue




Medical Devices

EV / Trailing LTM Revenue




Healthcare Technology

EV / Trailing LTM Revenue



Large, Diversified

EV / Trailing LTM Revenue




EBITDA Multiples

■ 75% Quartile ■ Median ■ 25% Quartile

Median EBITDA multiples from each MCM group. Data source: Bloomberg


Biotechnology & Life Sciences

EV / Trailing LTM EBITDA




Medical Devices

EV / Trailing LTM EBITDA




Healthcare Technology

EV / Trailing LTM EBITDA



Large, Diversified

EV / Trailing LTM EBITDA



Select Operating Metrics

Sector	TTM Gross Margin		TTM Operating Margin		TTM R&D / Revenue		TTM EBITDA Margin	
	3Q 2022	2Q 2022	3Q 2022	2Q 2022	3Q 2022	2Q 2022	3Q 2022	2Q 2022
Biotechnology & Life Sciences	66.3%	67.6%	21.1%	23.5%	20.1%	19.9%	25.1%	27.0%
Medical Devices	65.0%	64.8%	18.0%	18.5%	7.4%	7.1%	29.9%	30.0%
Healthcare Technology	59.2%	59.2%	4.2%	4.7%	13.3%	13.2%	20.3%	18.2%
Large, Diversified	57.1%	58.0%	21.0%	22.5%	8.5%	8.4%	34.4%	33.6%
Overall Median	63.4%	63.8%	18.7%	20.1%	7.9%	7.7%	29.1%	29.2%

Sector	Revenue Growth		L-T FWD Op. Earn. Growth		Debt / EV		Debt / EBITDA	
	Q / Q	Y / Y	3Q 2022	2Q 2022	3Q 2022	2Q 2022	3Q 2022	2Q 2022
Biotechnology & Life Sciences	0.2%	7.8%	14.7%	9.4%	7.9%	7.2%	1.5	1.5
Medical Devices	0.9%	7.8%	10.6%	11.0%	11.9%	8.9%	1.4	1.4
Healthcare Technology	3.6%	22.2%	8.3%	11.2%	14.1%	11.5%	1.1	1.0
Large, Diversified	0.2%	5.2%	6.3%	5.8%	20.7%	14.5%	2.3	2.3
Overall Median	0.9%	7.8%	8.5%	9.8%	11.9%	9.9%	1.6	1.6

Median measures for each group. | Data Source: Bloomberg

Public Medical Device Companies

		Price			Δ Stock Price		EV	TTM Rev	TTM EBITDA	FWD EBITDA		EV / Rev.	EV / EBITDA	EV / FWD EBITDA	
		3Q 2022	2Q 2022	3Q 2021	Qtrly	Annual	3Q 2022	3Q 2022	3Q 2022	FY 2023	FY 2024	3Q 2022	3Q 2022	2023	2024
Biotechnology & Life Sciences															
Biogen Inc	BIIB	\$267	\$204	\$283	30.9%	-5.7%	\$39,311	\$10,363	\$5,045	\$3,669	\$3,302	3.79x	7.8x	10.7x	11.9x
Bio-Rad Laboratories Inc	BIO	417	495	746	-15.7%	-44.1%	11,980	2,805	658	638	682	4.27	18.2	18.8	17.6
BioMarin Pharmaceutical Inc	BMRN	85	83	77	2.3%	9.7%	15,570	2,008	114	271	704	7.75	136.7	57.5	22.1
Sartorius Stedim Biotech	DIM	310	314	558	-1.1%	-44.3%	29,600	3,659	954	1,232	1,360	8.09	31.0	24.0	21.8
Eurofins Scientific SE	ERF	60	78	127	-22.9%	-52.7%	14,994	7,729	1,869	1,605	1,604	1.94	8.0	9.3	9.3
Gilead Sciences Inc	GILD	62	61	67	0.9%	-7.5%	95,637	27,136	12,489	12,948	12,569	3.52	7.7	7.4	7.6
Illumina Inc	ILMN	191	184	406	3.5%	-53.0%	31,479	4,698	(2,954)	678	828	6.70	nm	46.4	38.0
Incyte Corp	INCY	67	76	69	-12.3%	-3.1%	11,807	3,331	678	761	1,109	3.54	17.4	15.5	10.6
IQVIA Holdings Inc	IQV	181	217	240	-16.5%	-24.4%	44,948	14,307	3,049	3,343	3,632	3.14	14.7	13.4	12.4
Lonza Group AG	LONN	494	534	747	-7.4%	-33.8%	36,779	6,275	(508)	1,933	2,231	5.86	nm	19.0	16.5
Mettler-Toledo International Inc	MTD	1,084	1,149	1,377	-5.6%	-21.3%	26,026	3,899	1,207	1,225	1,300	6.67	21.6	21.2	20.0
Regeneron Pharmaceuticals Inc	REGN	689	591	605	16.5%	13.8%	64,660	13,710	6,898	6,072	5,805	4.72	9.4	10.6	11.1
Vertex Pharmaceuticals Inc	VRTX	290	282	181	2.8%	59.6%	65,363	8,701	4,503	5,068	5,617	7.51	14.5	12.9	11.6
Waters Corp	WAT	270	331	357	-18.6%	-24.6%	17,354	2,950	1,005	1,019	1,056	5.88	17.3	17.0	16.4
Group Median					-3.3%	-22.8%						5.29x	16.0x	16.3x	14.4x

(\$Millions, except per share figures)

Data Source: Bloomberg

Public Medical Device Companies (continued)

		Price			Δ Stock Price		EV	TTM Rev	TTM EBITDA	FWD EBITDA		EV / Rev.	EV / EBITDA	EV / FWD EBITDA	
		3Q 2022	2Q 2022	3Q 2021	Qtrly	Annual	3Q 2022	3Q 2022	3Q 2022	FY 2023	FY 2024	3Q 2022	3Q 2022	2023	2024
Medical Devices															
Terumo Corp	TRUMF	\$28	\$30	\$47	-6.1%	-40.1%	\$21,619	\$6,271	\$1,614	\$200,220	\$225,856	3.45x	13.4x	0.1x	0.1x
Sysmex Corp	SSMY	54	60	124	-10.4%	-56.7%	10,774	3,210	848	106,136	115,828	3.36	12.7	0.1	0.1
Olympus Corp	OCPNY	19	20	22	-4.5%	-12.4%	25,470	7,459	1,860	331,943	312,281	3.41	13.7	0.1	0.1
ABIOMED Inc	ABMD	246	248	326	-0.7%	-24.5%	10,174	1,003	324	286	340	10.14	31.4	35.6	29.9
Align Technology Inc	ALGN	207	237	665	-12.5%	-68.9%	15,157	3,864	873	905	917	3.92	17.4	16.7	16.5
Baxter International Inc	BAX	54	64	79	-15.7%	-32.0%	42,436	14,740	3,454	3,562	3,693	2.88	12.3	11.9	11.5
Boston Scientific Corp	BSX	39	37	43	3.9%	-10.7%	64,062	12,567	3,755	3,632	3,966	5.10	17.1	17.6	16.2
Coloplast A/S	COLOB	102	114	154	-10.4%	-33.5%	24,469	3,269	1,151	8,538	9,400	7.48	21.2	2.9	2.6
Edwards Lifesciences Corp	EW	83	95	113	-13.1%	-27.0%	50,129	5,364	1,843	1,934	1,965	9.35	27.2	25.9	25.5
Hologic Inc	HOLX	65	69	74	-6.9%	-12.6%	16,414	5,226	2,415	1,246	1,371	3.14	6.8	13.2	12.0
IDEXX Laboratories Inc	IDXX	326	351	622	-7.1%	-47.6%	28,360	3,340	1,014	1,011	1,162	8.49	28.0	28.0	24.4
Intuitive Surgical Inc	ISRG	187	201	331	-6.6%	-43.4%	61,909	6,118	2,040	2,523	2,870	10.12	30.3	24.5	21.6
ResMed Inc	RMD	218	209	261	4.3%	-16.6%	32,536	3,539	1,145	1,344	1,508	9.19	28.4	24.2	21.6
Smith & Nephew PLC	SN/	12	14	17	-15.2%	-30.6%	12,578	5,213	1,178	1,305	1,384	2.41	10.7	9.6	9.1
Stryker Corp	SYK	203	198	261	2.2%	-22.3%	88,368	17,948	4,785	4,702	5,180	4.92	18.5	18.8	17.1
Teleflex Inc	TFX	201	245	374	-17.9%	-46.3%	11,053	2,795	815	817	868	3.95	13.6	13.5	12.7
Zimmer Biomet Holdings Inc	ZBH	105	105	141	-0.3%	-25.8%	27,104	7,153	2,395	2,360	2,441	3.79	11.3	11.5	11.1
Group Median					-6.9%	-30.6%						3.95x	17.1x	13.5x	12.7x

(\$Millions, except per share figures)

Data Source: Bloomberg

Public Medical Device Companies (continued)

		Price			Δ Stock Price		EV	TTM Rev	TTM EBITDA	FWD EBITDA		EV / Rev.	EV / EBITDA	EV / FWD EBITDA	
		3Q 2022	2Q 2022	3Q 2021	Qtrly	Annual	3Q 2022	3Q 2022	3Q 2022	FY 2023	FY 2024	3Q 2022	3Q 2022	2023	2024
Healthcare Technology															
M3 Inc	MTHRY	\$28	\$29	\$71	-2.6%	-60.8%	\$17,923	\$1,815	\$672	\$86,954	\$97,936	9.87x	26.7x	0.2x	0.2x
Change Healthcare Inc	CHNG	25	21	19	19.2%	31.3%	12,908	3,335	969	1,070	1,165	3.87	13.3	12.1	11.1
Craneware PLC	CRW	21	22	32	-4.1%	-33.1%	841	118	30	55	60	7.14	28.5	15.2	14.0
Doximity Inc	DOCS	30	35	81	-13.2%	-62.6%	5,047	317	89	183	224	15.94	56.5	27.6	22.5
Evolent Health Inc	EVH	36	31	31	17.0%	15.9%	3,955	1,218	71	102	141	3.25	55.6	39.0	28.2
HealthStream Inc	HSTM	21	22	29	-2.1%	-25.6%	618	263	47	53	56	2.35	13.2	11.8	10.9
Allscripts Healthcare Solutions Inc	MDRX	15	15	13	2.7%	13.9%	1,390	837	191	174	200	1.66	7.3	8.0	7.0
NextGen Healthcare Inc	NXGN	18	17	14	1.5%	25.5%	1,168	589	97	112	125	1.98	12.0	10.4	9.4
Omniceil Inc	OMCL	87	114	148	-23.5%	-41.4%	4,237	1,309	167	196	202	3.24	25.3	21.6	21.0
Teladoc Health Inc	TDOC	25	33	127	-23.7%	-80.0%	4,800	2,323	3	242	295	2.07	1829.4	19.8	16.3
Tabula Rasa HealthCare Inc	TRHC	5	3	26	86.8%	-81.7%	386	302	(17)	8	17	1.28	nm	47.4	23.0
Veeva Systems Inc	VEEV	165	198	288	-16.7%	-42.8%	23,298	1,762	525	844	975	13.22	44.4	27.6	23.9
Group Median					-2.3%	-37.3%						3.24x	26.7x	17.5x	15.1x

(\$Millions, except per share figures)

Data Source: Bloomberg

Public Medical Device Companies (continued)

		Price			Δ Stock Price		EV	TTM Rev	TTM EBITDA	FWD EBITDA		EV / Rev.	EV / EBITDA	EV / FWD EBITDA	
		3Q 2022	2Q 2022	3Q 2021	Qtrly	Annual	3Q 2022	3Q 2022	3Q 2022	FY 2023	FY 2024	3Q 2022	3Q 2022	2023	2024
Large, Diversified															
Agilent Technologies Inc	A	\$121	\$118	\$156	2.5%	-22.4%	\$37,913	\$6,659	\$1,956	\$1,947	\$2,084	5.69x	19.4x	19.5x	18.2x
AbbVie Inc	ABBV	133	150	103	-11.6%	29.5%	292,676	57,819	32,253	33,071	28,010	5.06	9.1	8.8	10.4
Abbott Laboratories	ABT	96	108	116	-10.5%	-16.8%	174,263	45,030	13,315	12,498	10,550	3.87	13.1	13.9	16.5
Amgen Inc	AMGN	224	240	204	-6.6%	9.5%	146,654	26,330	14,744	14,963	15,016	5.57	9.9	9.8	9.8
Becton Dickinson and Co	BDX	223	246	236	-9.3%	-5.8%	77,345	19,782	6,800	5,350	5,503	3.91	11.4	14.5	14.1
Danaher Corp	DHR	258	253	303	2.0%	-14.9%	204,774	31,250	10,878	10,610	10,608	6.55	18.8	19.3	19.3
Johnson & Johnson	JNJ	163	176	157	-7.4%	3.8%	427,427	96,041	33,366	33,138	35,460	4.45	12.8	12.9	12.1
Medtronic PLC	MDT	81	89	122	-9.3%	-33.8%	121,276	31,785	9,844	9,751	10,224	3.82	12.3	12.4	11.9
Koninklijke Philips NV	PHIA	16	22	43	-27.3%	-63.4%	20,929	19,411	2,939	1,850	2,454	1.08	7.1	11.3	8.5
PerkinElmer Inc	PKI	120	142	173	-15.3%	-30.4%	19,323	4,565	1,602	1,454	1,099	4.23	12.1	13.3	17.6
Roche Holding AG	ROG	329	334	357	-1.6%	-7.8%	285,838	69,083	27,883	25,059	25,425	4.14	10.3	11.4	11.2
Siemens Healthineers AG	SHL	43	51	64	-15.7%	-33.2%	63,303	23,527	4,597	4,411	5,053	2.69	13.8	14.3	12.5
Thermo Fisher Scientific Inc	TMO	507	543	570	-6.6%	-11.0%	224,955	44,167	12,533	11,845	11,887	5.09	17.9	19.0	18.9
Group Median					-9.3%	-14.9%						4.23x	12.3x	13.3x	12.5x

(\$Millions, except per share figures)

Data Source: Bloomberg



Mergers & Acquisitions

Announced Transactions During 3Q 2022								
Acquirer	Target	Announce Date	Transaction Value	Implied EV	Implied EV			Target Sector
					Revenue	EBIT	EBITDA	
Pfizer Inc.	Global Blood Therapeutics, Inc.	8/8/22	\$5,551	\$5,033	21.43x	nm	nm	Biotechnology
Amgen Inc.	ChemoCentryx, Inc.	8/4/22	3,972	3,644	97.74	nm	nm	Biotechnology
SD Biosensor, Inc; SJL Partners	Meridian Bioscience, Inc.	7/7/22	1,564	1,481	4.31	17.3	14.2	Health Care Supplies
AmerisourceBergen Corporation	PharmaLex Holding GmbH	9/12/22	1,297	1,297	nm	nm	nm	Life Sciences Tools and Services
Novo Nordisk A/S	Forma Therapeutics Holdings, Inc.	9/1/22	1,060	664	nm	nm	nm	Biotechnology
McKesson Corporation	Rx Savings, LLC	9/19/22	875	875	nm	nm	nm	Health Care Technology
Sartorius Stedim Biotech S.A.	Albumedix Ltd.	8/8/22	503	503	nm	nm	nm	Biotechnology
Cadence Design Systems, Inc.	OpenEye Scientific Software, Inc.	7/25/22	474	461	nm	nm	nm	Health Care Technology
Arcutis Biotherapeutics, Inc.	Ducentis BioTherapeutics Limited	9/7/22	429	429	nm	nm	nm	Biotechnology
Innoviva, Inc.	La Jolla Pharmaceutical Company	7/11/22	326	277	5.96	nm	nm	Biotechnology
Vertex Pharmaceuticals Incorporated	ViaCyte, Inc.	7/11/22	315	296	nm	nm	nm	Biotechnology
Teleflex Incorporated	Standard Bariatrics, Inc.	8/22/22	300	300	nm	nm	nm	Health Care Equipment
Ultragenyx Pharmaceutical Inc.	GeneTx Biotherapeutics LLC	7/18/22	281	206	nm	nm	nm	Biotechnology
CONMED Corporation	Biorez, Inc.	8/1/22	251	250	nm	nm	nm	Health Care Equipment
Roche Holding AG	Good therapeutics, Inc.	9/7/22	250	250	nm	nm	nm	Biotechnology
DCC Healthcare Limited	Medi-Globe Technologies GmbH	9/8/22	244	244	0.28	nm	nm	Health Care Equipment
CARISMA Therapeutics Inc.	Sesen Bio, Inc.	9/21/22	189	na	nm	nm	nm	Biotechnology
ARS Pharmaceuticals, Inc.	Silverback Therapeutics, Inc.	7/21/22	189	na	nm	nm	nm	Biotechnology
URUS Group LP	Trans Ova Genetics LC	7/5/22	180	180	nm	nm	nm	Biotechnology
Bio-Rad Laboratories, Inc.	Curiosity Diagnostics Sp. z o.o.	8/3/22	171	171	nm	nm	nm	Biotechnology
Eurobio Scientific Société anonyme	Genome Diagnostics B.V.	8/17/22	137	137	7.94	nm	19.6	Health Care Equipment
Genfit S.A.	Versantis AG	9/19/22	109	109	nm	nm	nm	Biotechnology

Transaction values over \$100 million; Presented in \$millions

Data Source: Capital IQ

MedTech & Device M&A




Initial Public Offerings

Completed Initial Public Offerings During 3Q 2022								
Issuer	Ticker	IPO Date	IPO Price	Gross Proceeds (\$mil)	6/30/22 Stock Price	Return Since IPO	6/30/22 Market Cap	Industry
Nexalin Technology, Inc.	NasdaqCM:NXL	9/19/22	\$4.15	\$9.6	\$1.08	-74.0%	\$79	Health Care Equipment
eWeLL Co.,Ltd.	TSE:5038	9/16/22	11.89	21.9	25.68	116.0%	178.2	Health Care Technology
BioAffinity Technologies, Inc.	NasdaqCM:BIAF	9/1/22	6.13	7.9	2.91	-52.5%	21.4	Biotechnology
Shuttle Pharmaceuticals Holdings, Inc.	NasdaqCM:SHPH	8/30/22	8.13	10.0	4.59	-43.5%	54.8	Biotechnology
Innovative Eyewear, Inc.	NasdaqCM:LUCY	8/14/22	7.50	7.4	1.39	-81.5%	10.2	Health Care Supplies
MAIA Biotechnology, Inc.	NYSEAM:MAIA	7/27/22	5.00	10.0	3.30	-34.0%	36.1	Biotechnology

Data Source: Capital IQ

Initial Public Offerings (continued)

Medtech & Device IPOs



Source: Capital IQ; Mercer Capital Analysis



Mercer Capital

www.mercercapital.com

